Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMed

Allogeneic Stromal Vascular Fraction Accelerates Diabetic Wound Healing: A Cost-Effective Alternative to Adipose-Derived Stem Cells.

Demir H., Ozyazgan I., Gonen ZB., Yay AH., Mat OC., Gokdemir NS.

Animal Study on Diabetic Foot, Chronic Wound, published in Ann Plast Surg (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Ann Plast Surg (2026)
Country
United States
Reported sample size
—
Source database
PubMed
PMID
41842714
DOI
10.1097/SAP.0000000000004727

Abstract (original English)

Impaired wound healing in patients with diabetes mellitus is a major clinical problem resulting from chronic hyperglycemia, which disrupts immune function and prolongs inflammation. Cell-based therapies such as mesenchymal stem cells (MSCs) and stromal vascular fraction (SVF) have shown promise in promoting tissue repair, yet comparative data between SVF and adipose-derived stem cells (ADSCs) remain limited. In this experimental study, a diabetic rat model was used to compare the effects of allogeneic SVF and allogeneic ADSCs on wound healing. Wound areas were measured on days 5, 10, and 14. Histological analyses, including assessments of reepithelialization, fibrosis, and epithelial tongue length, as well as cytokine level measurements, were performed to evaluate tissue regeneration and inflammation. Both SVF and ADSC groups demonstrated significantly smaller wound areas compared with controls at all time points ( P <0.05). On days 5, 10, and 14, the wound areas were 3.127±0.382, 0.833±0.360, and 0.552±0.185 cm 2 in the control group; 1.968±0.533, 0.543±0.165, and 0.347±0.144 cm 2 in the SVF group; and 2.242±0.565, 0.432±0.137, and 0.276±0.131 cm 2 in the ADSC group, respectively. Histological evaluation revealed enhanced reepithelialization and greater epithelial tongue length in both treatment groups. No significant differences were observed between SVF and ADSC groups. IL-1

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AnimalsWound HealingRatsMaleDiabetes Mellitus, ExperimentalAdipose TissueStromal Vascular FractionTransplantation, HomologousCost-Benefit AnalysisStem Cell Transplantation

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research